A panelist discusses how identifying intermediate-risk patients, managing disease heterogeneity in non–muscle-invasive bladder cancer, and addressing long-term care needs present key challenges in ...

The ASPIRE trial showed SURE's noninferiority to URS in stone-free rate for nephrolithiasis treatment. SURE demonstrated superior stone clearance and residual stone volume outcomes, unaffected by ...

The therapeutic response rate was 79% at 24 months, which is comparable to the rates seen at 6 months (78%) and 12 months (82%).

“I think there's a lot to be done and combination therapies, other drugs that can be instilled into this device. It's a bright future,” says Siamak Daneshmand, MD. In this video, Siamak Daneshmand, MD ...

The series empowers surgeons to make informed family planning decisions through education, resources, and peer networking. Research indicates female surgeons face higher pregnancy complications and ...

New research better defines the link between cardiovascular disease risk and prevalence of ED per serum ceramide levels.

Vibegron is the first beta-3 agonist approved for OAB symptoms in men treated for BPH, showing significant symptom improvement. The phase 3 COURAGE trial demonstrated significant reductions in ...

"We found that with a 5-year Kaplan-Meier survival analysis that patients with varicocele had worse outcomes than patients without varicocele," says Muhammed A. Moukhtar Hammad, MBBCh. In this video, ...

home / case-based-peer-perspectives / optimizing-sequential-therapy-in-metastatic-castration-resistant-prostate-cancer-mcrpc-with-bone ...

What are the 5 stages of bladder health? We've talked a little bit about the Man vs Prostate campaign, and it's really important that it's built upon a principle of linguistic determinism. We really ...

“Some of the main implications for urologists is that the risk adapted utilization of BCG, which has been implemented as guidelines, should continue,” says Madison M. Wahlen. In this video, Madison M.